Why can drug-resistant parasites make sleeping sickness and malaria harder to treat?

Drug-resistant parasites make sleeping sickness and malaria harder to treat because they render once-effective medications incapable of destroying the organisms, allowing the infection to persist despite medical intervention.1

In the case of malaria, widespread resistance to drugs like chloroquine and, more recently, artemisinin has significantly complicated global control efforts. When parasites develop resistance, standard therapies fail to clear the infection, which can lead to an increase in disease incidence and severity.12

Similarly, for sleeping sickness, the development of drug-resistant strains of Trypanosoma brucei gambiense and T. brucei rhodesiense poses a major challenge to treatment. For example, resistance to the drug melarsoprol was identified in nearly 20 percent of patients in central Africa, necessitating a shift to alternative, often more complex, treatment regimens.13

The emergence of these resistant strains is a critical public health concern, as it undermines the efficacy of established antimalarial drugs and other antiparasitic agents, often forcing reliance on more toxic or less accessible alternatives.123